Zika Thrives in Pregnancy Due to Vulnerable Immune System

Share this content:
Zika Thrives in Pregnancy Due to Vulnerable Immune System
Zika Thrives in Pregnancy Due to Vulnerable Immune System

TUESDAY, Aug. 22, 2017 (HealthDay News) -- The Zika virus thrives in pregnant women by suppressing their already dampened immune systems and running roughshod over their body's natural defenses, which allows the virus to directly attack the fetus, according to a study published online Aug. 21 in Nature Microbiology.

Jae Jung, Ph.D., chair of the department of molecular microbiology and immunology at the University of Southern California's Keck School of Medicine in Los Angeles, and colleagues tested both the African and Asian strains of Zika in the blood samples of healthy men and women, as well as samples taken from pregnant women.

The researchers identified CD14+ monocytes as the primary target for both strains of infection. "About 5 percent of a pregnant woman's monocytes have immune-suppressive activity," Jung said. "African Zika virus pushes the 5 percent up to around 10 percent. By comparison, Asian Zika virus turns 70 percent of her monocytes toward immune-suppressing." Pregnancy was associated with an enhanced susceptibility to Zika virus infection.

"Specifically, Asian-lineage Zika virus infection of pregnant women's blood led to an exacerbated M2-skewed immunosuppression of non-classical monocytes in conjunction with a global suppression of type I interferon-signaling pathway and an aberrant expression of host genes associated with pregnancy complications," the authors write. "Also, 30 Zika virus-positive sera from symptomatic pregnant patients showed elevated levels of M2-skewed immunosuppressive cytokines and pregnancy-complication-associated fibronectin-1."

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »